Nektar Therapeutics Shares Outstanding 2006-2020 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2019 175
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2020-03-31 177
2019-12-31 175
2019-09-30 175
2019-06-30 175
2019-03-31 174
2018-12-31 180
2018-09-30 173
2018-06-30 182
2018-03-31 161
2017-12-31 156
2017-09-30 163
2017-06-30 155
2017-03-31 154
2016-12-31 140
2016-09-30 137
2016-06-30 136
2016-03-31 136
2015-12-31 132
2015-09-30 133
2015-06-30 132
2015-03-31 136
2014-12-31 127
2014-09-30 132
2014-06-30 127
2014-03-31 124
2013-12-31 116
2013-09-30 116
2013-06-30 116
2013-03-31 115
2012-12-31 115
2012-09-30 115
2012-06-30 115
2012-03-31 115
2011-12-31 113
2011-09-30 114
2011-06-30 114
2011-03-31 109
2010-12-31 94
2010-09-30 94
2010-06-30 94
2010-03-31 94
2009-12-31 93
2009-09-30 93
2009-06-30 93
2009-03-31 93
2008-12-31 92
2008-09-30 92
2008-06-30 92
2008-03-31 92
2007-12-31 92
2007-09-30 92
2007-06-30 92
2007-03-31 91
2006-12-31 90
2006-09-30 90
2006-06-30 90
2006-03-31 89
2005-12-31 86
2005-09-30 86
2005-06-30 85
2005-03-31 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.186B $0.115B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.380B 37.10
Takeda Pharmaceutical (TAK) Japan $56.087B 9.83
Astellas Pharma (ALPMY) Japan $30.738B 0.00
Eisai (ESALY) Japan $23.358B 20.25
UCB SA (UCBJF) Belgium $22.796B 0.00
Merck (MKGAF) Germany $15.419B 0.00
Grifols, S.A (GRFS) Spain $12.857B 15.98
Neurocrine Biosciences (NBIX) United States $11.643B 53.81
Catalent (CTLT) United States $11.267B 43.56
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 0.00
Ionis Pharmaceuticals (IONS) United States $8.469B 45.03
IPSEN SA ADR (IPSEY) France $7.049B 0.00
Orion OYJ (ORINY) Finland $6.766B 30.32
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.664B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.074B 9.72
United Therapeutics (UTHR) United States $5.296B 10.04
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $4.498B 491.11
Evotec AG (EVTCY) Germany $4.104B 110.61
FibroGen (FGEN) United States $3.876B 0.00
Hypermarcas (HYPMY) Brazil $3.819B 0.00
ChemoCentryx (CCXI) United States $3.588B 0.00
PTC Therapeutics (PTCT) United States $3.470B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.581B 10.60
Sage Therapeutics (SAGE) United States $2.233B 0.00
Pacira BioSciences (PCRX) United States $2.206B 45.15
Cronos Group (CRON) Canada $2.152B 61.70
Corcept Therapeutics (CORT) United States $1.969B 19.52
Xencor (XNCR) United States $1.871B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.752B 0.00
USANA Health Sciences (USNA) United States $1.729B 17.74
Akebia Therapeutics (AKBA) United States $1.704B 0.00
Indivior (INVVY) United States $1.679B 20.84
Ironwood Pharmaceuticals (IRWD) United States $1.622B 12.41
Zogenix (ZGNX) United States $1.615B 0.00
Karyopharm Therapeutics (KPTI) United States $1.441B 0.00
Portola Pharmaceuticals (PTLA) United States $1.415B 0.00
Heron Therapeutics (HRTX) United States $1.408B 0.00
Esperion Therapeutics (ESPR) United States $1.407B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.353B 14.58
Theravance Biopharma (TBPH) Cayman Islands $1.295B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.250B 0.00
Translate Bio (TBIO) United States $1.124B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.999B 44.59
BioCryst Pharmaceuticals (BCRX) United States $0.886B 0.00
Tilray (TLRY) Canada $0.869B 0.00
ImmunoGen (IMGN) United States $0.851B 0.00
Endo (ENDP) Ireland $0.802B 1.24
Radius Health (RDUS) United States $0.657B 0.00
Trillium Therapeutics (TRIL) Canada $0.657B 0.00
Aerie Pharmaceuticals (AERI) United States $0.649B 0.00
Ardelyx (ARDX) United States $0.624B 0.00
Molecular Templates (MTEM) United States $0.618B 0.00
Collegium Pharmaceutical (COLL) United States $0.600B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.576B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.556B 0.00
VAXART, INC (VXRT) United States $0.547B 0.00
Flexion Therapeutics (FLXN) United States $0.511B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.497B 12.02
Siga Technologies (SIGA) United States $0.484B 0.00
Innate Pharma SA (IPHYF) France $0.476B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.458B 17.89
DURECT (DRRX) United States $0.439B 0.00
Ocular Therapeutix (OCUL) United States $0.426B 0.00
Harpoon Therapeutics (HARP) United States $0.415B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.399B 0.00
Organogenesis Holdings (ORGO) United States $0.395B 0.00
TherapeuticsMD (TXMD) United States $0.378B 0.00
MEI Pharma (MEIP) United States $0.370B 0.00
Calithera Biosciences (CALA) United States $0.363B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.322B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.298B 0.00
OptiNose (OPTN) United States $0.296B 0.00
Lannett Co Inc (LCI) United States $0.287B 6.30
PROFOUND MEDICL (PROF) Canada $0.281B 0.00
Concert Pharmaceuticals (CNCE) United States $0.275B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.250B 0.00
CASI Pharmaceuticals (CASI) United States $0.245B 0.00
Redhill Biopharma (RDHL) Israel $0.239B 0.00
KalVista Pharmaceuticals (KALV) United States $0.231B 0.00
Jounce Therapeutics (JNCE) United States $0.222B 5.29
Rafael Holdings (RFL) United States $0.222B 0.00
Taiwan Liposome (TLC) Taiwan $0.215B 0.00
Nivalis Therapeutics (ALPN) United States $0.189B 0.00
Nature's Sunshine Products (NATR) United States $0.177B 23.33
IMV INC (IMV) Canada $0.176B 0.00
Altimmune (ALT) United States $0.162B 0.00
Aquestive Therapeutics (AQST) United States $0.158B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.147B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.120B 0.00
Champions Oncology (CSBR) United States $0.117B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.110B 0.00
Recro Pharma (REPH) United States $0.108B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.106B 0.00
Xeris Pharmaceuticals (XERS) United States $0.105B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.102B 0.00
Onconova Therapeutics (ONTX) United States $0.098B 0.00
Otonomy (OTIC) United States $0.098B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.096B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.095B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.092B 0.00
MediWound (MDWD) Israel $0.092B 0.00
CTI BioPharma (CTIC) United States $0.087B 0.00
Sundial Growers (SNDL) Canada $0.084B 0.00
Biomerica (BMRA) United States $0.083B 0.00
Heat Biologics (HTBX) United States $0.074B 0.00
SCYNEXIS (SCYX) United States $0.071B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.067B 0.00
Aclaris Therapeutics (ACRS) United States $0.063B 0.00
Lipocine (LPCN) United States $0.063B 0.00
CV Sciences (CVSI) United States $0.060B 0.00
RENEURON GP (RNUGF) United Kingdom $0.057B 0.00
Addex Therapeutics (ADXN) Switzerland $0.052B 0.00
Infinity Pharmaceuticals (INFI) United States $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.049B 29.45
PolarityTE (PTE) United States $0.048B 0.00
Natural Alternatives (NAII) United States $0.047B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.043B 0.00
GTx (ONCT) United States $0.042B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.042B 0.00
Forward Pharma (FWP) Denmark $0.042B 0.00
Mannatechorporated (MTEX) United States $0.041B 7.71
Adamis Pharmaceuticals (ADMP) United States $0.040B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.039B 83.00
Novan (NOVN) United States $0.039B 0.00
Neos Therapeutics (NEOS) United States $0.034B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.028B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
Iterum Therapeutics (ITRM) Ireland $0.021B 0.00
Flex Pharma (SLRX) United States $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.018B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
China SXT Pharmaceuticals (SXTC) China $0.015B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Shineco (TYHT) China $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 33.86
Sonoma Pharmaceuticals (SNOA) United States $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.010B 0.00
Vical (BBI) United States $0.010B 0.00
Midatech Pharma (MTP) United Kingdom $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.009B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00